Cantargia confirms enrollment in Phase IIa trial for CAN04 monotherapy
Category: #health  By Mateen Dalal  Date: 2019-07-06
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Cantargia confirms enrollment in Phase IIa trial for CAN04 monotherapy

All the 20 patients for the monotherapy arm of the trial have begun treatment with 10 mg/kg dosage level

Swedish biotech firm Cantargia has reportedly announced full recruitment of CAN04 monotherapy arm in an existing Phase IIa clinical study in cancer patients.

Sources with knowledge on the matter informed that CAN04 (nidanilimab) is an antibody from Cantargia which is being investigated in a three-armed open label Phase IIa trial CANFOUR. Under this, CAN04 is evaluated as monotherapy or in chemotherapy combinations in pancreatic cancer (PDAC) or non-small cell lung cancer (NSCLC) patients.

All the 20 patients for the monotherapy arm of the trial have begun treatment with 10 mg/kg dose. The Safety, overall, has been in line with Phase I results. Outcome of the monotherapy, including efficacy and biomarkers are expected to be ready during fourth quarter of 2019, the sources informed.

Cantargia, on the basis of fast recruitment and good safety, is planning to utilize this opportunity to add more patients for generating safety and biomarker data at higher dosage level. Enrollment for the combination arms is also ongoing parallel to the monotherapy arm.

Sources stated that tumor biopsies have been obtained from most for the patients in the study, which were taken before and after therapy. Analyzing these biopsies will provide insights into the impact of CAN04 in the tumor microenvironment. Biomarkers would also be analyzed in the serum and the outcomes of these analyses are expected together with the efficacy results from CT-sans, sources added.

For the uninitiated, Cantargia develops pharmaceuticals based on antibodies against the interleukin 1 receptor accessory protein, or IL1RAP. IL1RAP with high functions and affinity is bound by antibody CAN04 through blockade of interleukin 1 signaling as well as ADCC. Apparently, almost 70% of PDAC patients and 80% of NSCLC patients overexpress IL1RAP on cancer cells, while in these diseases every patient has cells containing IL1RAP in the tumor microenvironment.

Source Credits: https://cantargia.com/en/press-releases/cantargia-announce-full-recruitment-of-can04-monotherapy-arm-in-ongoing-phase-iia-clinical-trial

 

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

Chevrolet Camaro could be replaced by a potential all-electric sedan

Chevrolet Camaro could be replaced by a potential all-electric sedan

By Mateen Dalal

Reportedly, General Motors Company is planning to replace the Chevrolet Camaro with an all-electric performance sedan in a few years with the existing model likely to be phased out by 2024. There have many reports about discontinuing the Camaro&rsqu...

Sequoia India launches Spark Fellowship to support female entrepreneurs

Sequoia India launches Spark Fellowship to support female entrepreneurs

By Mateen Dalal

The Spark fellowship program is for women entrepreneurs in India and Southeast Asia. The year-long program is aimed at bringing more gender diversity and supporting startups led by women. Sequoia Capital has recently revealed the launch of a yea...

Biden names avid tech critic Jonathan Kanter as DOJ antitrust chief

Biden names avid tech critic Jonathan Kanter as DOJ antitrust chief

By Mateen Dalal

U.S. President Joe Biden will reportedly nominate Jonathan Kanter, a competition lawyer, and fervid Google critic, to head the antitrust division of the Justice Department. Kanter has been actively representing several companies in competition cases...